Maze Therapeutics (MAZE) Corporate presentation summary

Strategic focus and platform

• Specializes in precision small molecule medicines for kidney and metabolic diseases, leveraging human genetics and the proprietary Compass platform for target discovery and drug development.

• Pipeline targets genetically validated pathways, including APOL1 and SLC6A19, with a focus on diseases with high unmet need.

• Ongoing research and discovery efforts aim to expand indications and identify new candidates in kidney and metabolic diseases, including obesity.

Lead program: MZE829 for APOL1-mediated kidney disease (AMKD)

• MZE829 is a dual-mechanism APOL1 inhibitor designed to address AMKD, a disease disproportionately affecting people of African ancestry, with no approved therapies.

• Phase 1 data showed favorable safety, dose-proportional PK, and no significant adverse events; 250 mg QD selected for Phase 2.

• Phase 2 HORIZON study is enrolling broad AMKD patients, with topline proof-of-concept data expected by end of Q1 2026.

• ≥30% reduction in uACR is considered clinically meaningful and will inform advancement to later-stage trials.

MZE782 for phenylketonuria (PKU) and chronic kidney disease (CKD)

• MZE782 is an oral substrate reduction therapy targeting SLC6A19, with potential to benefit a broad spectrum of PKU patients and reduce dietary burden.

• Phase 1 data in healthy volunteers showed excellent safety, linear PK, and up to 42x increase in urinary phenylalanine excretion.

• Phase 2 trial in PKU planned for mid-2026; Phase 2 in CKD to start in 2H 2026.

• Preclinical and early clinical data support SLC6A19 inhibition as a novel approach for CKD, with potential as monotherapy or add-on to standard of care.